TSIDS02:	Subject Disposition; [Randomized/Enrolled] Analysis Set (Study jjcs - core)							
 	Active Study Agent 	Active Study Agent 	 	 	Risk Difference (%) 95% CI 	Risk Difference (%) 95% CI 	
 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	Total 	Xanomeline High Dose vs Placebo 	Xanomeline Low Dose vs Placebo 	
  	N=84 	N=84 	N=86 	N=254 	  	  	
Analysis set 	 	 	 	 	 	 	
Full 	84 (100.0%) 	84 (100.0%) 	86 (100.0%) 	254 (100.0%) 	 	 	
Safety 	64 (76.2%) 	62 (73.8%) 	59 (68.6%) 	185 (72.8%) 	 	 	
Per protocol 	64 (76.2%) 	62 (73.8%) 	59 (68.6%) 	185 (72.8%) 	 	 	
 	  	  	  	  	  	  	
Subjects ongoing 	18 (21.4%) 	15 (17.9%) 	14 (16.3%) 	47 (18.5%) 	 	 	
 	  	  	  	  	  	  	
Completed treatment 	19 (22.6%) 	21 (25.0%) 	49 (57.0%) 	89 (35.0%) 	-34.4 (-48.1, -20.6) 	-32.0 (-45.9, -18.0) 	
Discontinued treatment 	49 (58.3%) 	43 (51.2%) 	22 (25.6%) 	114 (44.9%) 	32.8 (18.7, 46.8) 	25.6 (11.5, 39.7) 	
Other 	49 (58.3%) 	43 (51.2%) 	22 (25.6%) 	114 (44.9%) 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
 	  	  	  	  	  	  	
Completed study 	22 (26.2%) 	21 (25.0%) 	48 (55.8%) 	91 (35.8%) 	-29.6 (-43.7, -15.5) 	-30.8 (-44.8, -16.8) 	
Discontinued study 	44 (52.4%) 	48 (57.1%) 	24 (27.9%) 	116 (45.7%) 	24.5 (10.2, 38.8) 	29.2 (15.0, 43.4) 	
Other 	44 (52.4%) 	48 (57.1%) 	24 (27.9%) 	116 (45.7%) 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0)